Literature DB >> 15949575

Acquired inv(9): what is its significance?

Jaime L Betz1, Ahmed S Behairy, Pedro Rabionet, Budi Tirtorahardjo, Mathew W Moore, Philip D Cotter.   

Abstract

Pericentric inversion of the heterochromatic region of chromosome 9 [inv(9)] is a common heteromorphism in the general population. It is presumed familial as there are no reports of de novo inv(9) chromosomes in constitutional karyotypes. We report 2 cases of acquired inv(9) chromosomes; 1 patient with acute myeloid leukemia, 46,XY,inv(9)(p11q13)[11]/46,XY[9], and a second with severe anemia, 46,XX,inv(9)(p11q13)[14]/46,XX[6]. The acquired nature of the inv(9) was confirmed by constitutional karyotyping and/or molecular analysis. The inv(9) in these patients may be a de novo inversion that cytogenetically mimics the constitutional inv(9) heteromorphism. Alternatively, it may be the result of neocentromere activation in 9q due to epigenetic events associated with the disease in these patients that results in a metacentric chromosome similarly mimicking the constitutional inv(9). One previous report of an acquired inv(9) was in a patient with essential thrombocythemia. The differences in clinical presentation may represent different underlying mechanisms generating the inv(9). The significance of an acquired inv(9) is unknown and will require reporting of additional cases.

Entities:  

Mesh:

Year:  2005        PMID: 15949575     DOI: 10.1016/j.cancergencyto.2004.12.002

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  6 in total

Review 1.  Mouse chromosome engineering for modeling human disease.

Authors:  Louise van der Weyden; Allan Bradley
Journal:  Annu Rev Genomics Hum Genet       Date:  2006       Impact factor: 8.929

Review 2.  Persistent craniopharyngeal canal, bilateral microphthalmia with colobomatous cysts, ectopic adenohypophysis with Rathke cleft cyst, and ectopic neurohypophysis: case report and review of the literature.

Authors:  Nazlı Gülsüm Akyel; Ayşe Gül Alımlı; Tülin Hakan Demirkan; Mesut Sivri
Journal:  Childs Nerv Syst       Date:  2018-02-14       Impact factor: 1.475

3.  Successful all-trans retinoic acid treatment of acute promyelocytic leukemia in a patient with NPM/RAR fusion.

Authors:  Kiyoshi Okazuka; Masayoshi Masuko; Yoshinobu Seki; Hitomi Hama; Noriyuki Honma; Tatsuo Furukawa; Ken Toba; Kenji Kishi; Yoshifusa Aizawa
Journal:  Int J Hematol       Date:  2007-10       Impact factor: 2.490

4.  Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation.

Authors:  Matjaz Sever; Hagop Kantarjian; Sherry Pierce; Nitin Jain; Zeev Estrov; Jorge Cortes; Srdan Verstovsek
Journal:  Int J Hematol       Date:  2009-08-29       Impact factor: 2.490

5.  Acquired pericentric inversion of chromosome 9 in acute myeloid leukemia.

Authors:  A M Udayakumar; A V Pathare; D Dennison; J A Raeburn
Journal:  J Appl Genet       Date:  2009       Impact factor: 3.240

6.  Heteromorphic variants of chromosome 9.

Authors:  Nadezda Kosyakova; Ani Grigorian; Thomas Liehr; Marina Manvelyan; Isabella Simonyan; Hasmik Mkrtchyan; Rouben Aroutiounian; Anna D Polityko; Anna I Kulpanovich; Tatiana Egorova; Evgenia Jaroshevich; Alla Frolova; Natalia Shorokh; Irina V Naumchik; Marianne Volleth; Isolde Schreyer; Heike Nelle; Markus Stumm; Rolf-Dieter Wegner; Gisela Reising-Ackermann; Martina Merkas; Lukretija Brecevic; Thomas Martin; Laura Rodríguez; Samarth Bhatt; Monika Ziegler; Katharina Kreskowski; Anja Weise; Ali Sazci; Svetlana Vorsanova; Marcelo de Bello Cioffi; Emel Ergul
Journal:  Mol Cytogenet       Date:  2013-04-01       Impact factor: 2.009

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.